. >> my questions are of mr. beall. the cystic fibrosis foundation has done great collaborative work that has resulted in successful marketing of -- and recent positive complimentary drug that may extend treatment to half the patients with cf. but i want to ask you about a couple of points in your testimony. you talk about the cf foundation's strong relationship with the fda and the important of bringing good data to the table when consulting with the fda which i know is true. i want to hear more about that relationship. we are hearing about the need for the fda to seek and incorporate patient input into the review process. can you tell us more about the cf foundation's interaction with the fda and are there lessons that can be learned by other disease groups? >> i can give you a perfect example. on wednesday of this week we had three officials including dr. robert temple who is in the drug division at our offices talking about the development of clinical trials protocols of drugs that might not into clinical trials thr

my questions are of mr. beall.ive work that is resulted not only in successful marketing of kalydeco but also the recent positive test result of the company to drug that makes treatment of nearly half of all patients with cf and, of course, i commend you for your efforts. i wanted to ask about a couple of points in your test with the you spoke about the cf foundation strong relationship with the fda and the board to bring good data to the table when consulting with the fda, which i know is true, and i like her more about that relationship. we are hearing a lot today about the need for fda to do more to seek and incorporate patient input into its review process. the basic question, can you tell us more about the cf foundation's interaction with the fda? are there any lessons that can be learned by other disease groups? >> i can give you a perfect sample because of wednesday this week with three officials, including doctor temple who's in the drug division at our office is talking about the development of clinical tr